Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 506
Filter
1.
Biomédica (Bogotá) ; 42(2): 278-289, ene.-jun. 2022. tab
Article in Spanish | LILACS | ID: biblio-1403581

ABSTRACT

Introducción. Entre el 80 y el 95 % de los pacientes infectados por el virus de inmunodeficiencia humana (HIV) desarrollan manifestaciones en la piel que sirven como marcadores de su estado inmunológico. Objetivos. Describir las manifestaciones dermatológicas y los factores clínicos y sociodemográficos de los pacientes hospitalizados con diagnóstico de HIV y su correlación con el recuento de linfocitos T CD4. Materiales y métodos. Se hizo un estudio observacional de corte transversal y retrospectivo a partir del registro de las historias clínicas de 227 pacientes mayores de edad con diagnóstico de HIV, evaluados por dermatología en un hospital de Medellín, Colombia. Resultados. Los 227 registros daban cuenta de 433 manifestaciones dermatológicas, el 64,4 % de ellas infecciosas. Las tres manifestaciones más frecuentes fueron candidiasis oral, condilomas acuminados y reacciones a medicamentos. Se encontró una relación estadísticamente significativa entre el virus del herpes zóster (HZ) diseminado y la sífilis secundaria, con un recuento de CD4 entre 200 y 499 células/mm3 (p=0,04 y 0,028, respectivamente), y entre la candidiasis oral y un recuento de CD4 menor de 100 células/ mm3 (p=0,008). Conclusiones. La relación entre el herpes zóster diseminado y un recuento de CD4 entre 200 y 499 células/mm3 sugiere que, a pesar de los recuentos altos, se pueden presentar formas graves de la enfermedad debido a una posible disfunción de las células T y el agotamiento del sistema inmunológico. La relación entre la candidiasis oral y un recuento de CD4 menor de 100 células/mm3 plantea la posibilidad de considerar esta infección micótica como un marcador importante de debilitamiento inmunológico de los pacientes con HIV.


Introduction. About 80-95% of patients infected with the human immunodeficiency virus (HIV) develop skin manifestations, which are markers of the patients' immune status. Objective. To describe the dermatologic manifestations and the clinical and sociodemographic factors of hospitalized patients diagnosed with HIV and their correlation with CD4 T-lymphocyte count. Materials and methods. We conducted an observational, cross-sectional, and retrospective study of the medical records of 227 adult patients with HIV diagnosis evaluated by dermatology in a hospital in Medellín, Colombia. Results. We included 227 patient records with 433 dermatologic manifestations, 64.4% of them infectious. The most frequent manifestations were oral candidiasis, condylomata acuminata, and drug reactions. Moreover, a statistically significant relationship was found between disseminated herpes zoster virus and secondary syphilis with a CD4 count between 200-499 cells/mm3 (p=0.04 and 0.028, respectively). There was also a statistically significant relationship between oral candidiasis and a CD4 count of less than 100 cells/ mm3 (p=0.008). Conclusions. The relationship between disseminated herpes zoster with CD4 between 200-499 cells/mm3 suggests that, despite having high CD4 counts, severe forms of the disease may occur due to possible T-cell dysfunction and depletion of the immune system. Additionally, the relationship between oral candidiasis and CD4 less than 100 cells/mm3 indicates the potential role of oral candidiasis as an essential marker of weakened immune status in HIV patients.


Subject(s)
HIV , Dermatology , Epidemiology , Acquired Immunodeficiency Syndrome , Immunosuppression Therapy , Drug Eruptions , Drug Hypersensitivity , Infections
2.
Salud(i)ciencia (Impresa) ; 25(2): 93-96, 2022. tab./fot.
Article in Spanish | LILACS | ID: biblio-1436333

ABSTRACT

Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) is a benign, self-limited, immune-mediated, symmetric erythematous rash involving the buttocks and other intertriginous/flexural areas, observed after systemic exposure to a drug in an individual with or without prior sensitization. We present a 70-year old patient, who presented SDRIFE after the administration of piperacillin-tazobactam which improved rapidly after its suspension.


El exantema intertriginoso y flexural simétrico relacionado con fármacos (SDRIFE, por su sigla en inglés) es una erupción eritematosa simétrica, inmunomediada, benigna y autolimitada, que compromete glúteos y otras áreas intertriginosas, flexurales o ambas, y que se observa luego de la exposición sistémica a un fármaco en un individuo con sensibilización previa o sin ella. Se comenta el caso clínico de un paciente de 70 años de edad, que presentó SDRIFE posterior a la administración de piperacilina-tazobactam y que mejoró rápidamente luego de su suspensión.


Subject(s)
Exanthema , Drug Eruptions , beta-Lactams , Dermatitis , Piperacillin, Tazobactam Drug Combination , Intertrigo
3.
Rev. Hosp. Ital. B. Aires (2004) ; 41(4): 180-185, dic. 2021. ilus, tab
Article in Spanish | LILACS, UNISALUD, BINACIS | ID: biblio-1366880

ABSTRACT

El síndrome de intolerancia a múltiples medicamentos (MDIS, por sus siglas en inglés) se caracteriza por la intolerancia a dos o más medicamentos no relacionados. Tiene una prevalencia baja y es común en pacientes con polifarmacia. A pesar de que las reacciones adversas a los medicamentos son muy frecuentes, es raro que los pacientes debuten con este síndrome, el cual tiene implicaciones clínicas de leves a graves que afectan su vida; de acuerdo con esto varían el abordaje y su manejo. La sintomatología presentada varía desde síntomas gastrointestinales como reflujo gastroesofágico, dolores musculares y cefalea, hasta síntomas cutáneos; estos son los más frecuentes, tales como urticaria y erupciones maculopapulares o presentaciones menos comunes como el síndrome de Stevens-Johnson. El MDIS es causado por una amplia variedad de fármacos; por ello el conocimiento del síndrome, así como un adecuado interrogatorio de los antecedentes del paciente, es necesario para realizar un diagnóstico oportuno e instaurar un manejo adecuado y preventivo, evitando reacciones adversas que pongan en riesgo su vida. Con los hallazgos del cuadro clínico en la paciente, y basados en los antecedentes alérgicos presentados anteriormente a diferentes medicamentos no relacionados entre ellos, más la presentación de un rash maculopapular generalizado posterior a la administración de trimetoprim/sulfametoxazol se realiza el diagnóstico de MDIS. Se decide cambiar de medicamento por fosfomicina, con una consecuente evolución favorable. (AU)


Subject(s)
Humans , Female , Adult , Drug Eruptions/diagnosis , Drug Hypersensitivity Syndrome/diagnosis , Drug Hypersensitivity Syndrome/physiopathology , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects , Loratadine/administration & dosage , Polypharmacy , Fosfomycin/administration & dosage
4.
Article in English | LILACS | ID: biblio-1353510

ABSTRACT

ABSTRACT: Drug reactions with eosinophilia and systemic symptoms (DRESS) are rare and potentially fatal adverse hypersen-sitivity reaction to some drugs, especially anticonvulsants.The syndrome affects not only the skin but also other organs, especially the liver. The incidence can vary from 1 to 5 cases per 10.000 patients exposed to anticonvul-sants. The recognition of the syndrome is of fundamental importance since the mortality rate is between 10 and 40%. Once the diagnosis is established, the triggering drug must be identified and discontinued. Corticosteroids are usually associated with therapy. Autoimmune sequelae have been reported, including vitiligo and rarely alopecia. Alopecia universalis is a variant of alopecia areata, characterized by hair loss throughout the body. We report a case of DRESS, associated with two autoimmune dermatological diseases: alopecia universalis and vitiligo. (AU)


RESUMO: A reação a drogas com eosinofilia e sintomas sistêmicos (DRESS) é uma rara e potencialmente fatal reação adversa de hipersensibilidade, decorrente de alguns medicamentos, principalmente os anticonvulsivantes. A síndrome não afeta apenas a pele, mas também outros órgãos, principalmente o fígado. A incidência pode variar de 1 a 5 casos por 10.000 pacientes expostos aos anticonvulsivantes. O reconhecimento da síndrome é de fundamental importân-cia devido a taxa de mortalidade entre 10-40%. Uma vez estabelecido o diagnóstico, deve-se identificar o medica-mento desencadeante e suspendê-lo. O corticosteróide geralmente é associado na terapia. Sequelas autoimunes foram relatadas, incluindo vitiligo e raramente alopecia. A alopecia universal é uma variante da alopecia areata, caracterizada pela perda de pelos em todo o corpo. Relatamos um caso de DRESS, associado a duas doenças au-toimunes dermatológicas: alopecia universal e vitiligo. (AU)


Subject(s)
Humans , Male , Adult , Vitiligo , Drug Eruptions , Drug Hypersensitivity , Eosinophilia , Drug Hypersensitivity Syndrome , Anticonvulsants
6.
Arq. Asma, Alerg. Imunol ; 4(3): 347-353, jul.set.2020. ilus
Article in Portuguese | LILACS | ID: biblio-1382008

ABSTRACT

A erupção fixa à droga (EFD) é uma reação de hipersensibilidade tardia a medicamentos caracterizada por máculas ou pápulas eritematosas, violáceas ou acastanhadas, bem demarcadas, que aparecem após uso de uma medicação, e reaparecem na mesma localização após exposições repetidas. A erupção fixa à droga bolhosa generalizada (EFDBG) é uma variante rara da EFD que foi recentemente incluída pelo RegiSCAR no grupo das farmacodermias graves. Apresenta-se através de lesões cutâneas generalizadas características de EFD, com formação de bolhas, geralmente em pacientes com história prévia de EFD. Os principais medicamentos envolvidos na EFDBG são antibióticos e anti-inflamatórios não esteroidais. O diagnóstico é clínico, entretanto, a biópsia cutânea na fase aguda e o teste de contato após a recuperação do paciente, podem auxiliar a investigação. O tratamento requer geralmente apenas a suspensão do fármaco suspeito e medidas de suporte. Relatamos um caso de EFDBG em adolescente após reexposição à dipirona (metamizol) apesar da história prévia de hipersensibilidade a esta medicação. O objetivo deste relato é alertar sobre a importância do diagnóstico da EFDBG e ressaltar os principais pontos para o diagnóstico diferencial com a síndrome de Stevens-Johnson (SSJ)/necrólise epidérmica tóxica (NET).


Fixed drug eruption (FDE) is a delayed drug hypersensitivity reaction characterized by erythematous, violaceous or brownish well-demarcated macules or papules that appear after use of a medication and reappear at the same site after repeated exposures. Generalized bullous fixed drug eruption (GBFDE) is a rare FDE variant that has been recently included by RegiSCAR in the group of severe cutaneous adverse reactions to drugs. GBFDE presents as generalized cutaneous lesions characteristic of FDE, with blistering, usually in patients with a previous history of FDE. The main drugs involved in GBFDE are antibiotics and nonsteroidal anti-inflammatory drugs. The diagnosis is clinical, but some tests can help the investigation, such as skin biopsy in the acute phase and patch testing after patient recovery. Treatment usually requires suspension of the suspected drug and some supportive measures. We report a case of GBFDE after reexposure to dipyrone (metamizole) in an adolescent with a previous history of hypersensitivity to this drug. The aim of this report is to warn about the importance of diagnosing GBFDE and to highlight the main points for differential diagnosis with Stevens- Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN).


Subject(s)
Humans , Male , Adolescent , Dipyrone , Drug Eruptions , Drug Hypersensitivity , Patients , Betamethasone , Prednisolone , Skin Tests , Anti-Inflammatory Agents, Non-Steroidal , Stevens-Johnson Syndrome , Diagnosis, Differential
7.
Rev. inf. cient ; 99(2): 134-141, mar.-abr. 2020. tab
Article in Spanish | LILACS, CUMED | ID: biblio-1126929

ABSTRACT

RESUMEN Introducción: En Guantánamo no se encuentra ningún estudio que aborde las reacciones cutáneas adversas medicamentosas (RCAM), necesidad sentida por el claustro de dermatólogos del territorio. Objetivo: Caracterizar las reacciones cutáneas adversas medicamentosas en pacientes atendidos en el Servicio de Dermatología del Hospital General Docente "Dr. Agostinho Neto" de Guantánamo en el período 2018-2019. Método: Se realizó un estudio descriptivo y transversal con todos los pacientes (N=75) con el diagnóstico de reacciones cutáneas adversas medicamentosas remitidos a la consulta de Dermatología del Hospital General Docente "Dr. Agostinho Neto", se precisó el medicamento que originó la reacción, diagnóstico clínico, tipo de reacción, tiempo de evolución desde la ingestión del fármaco hasta la aparición de los síntomas, número de reacciones y conducta médica. Resultados: Estas reacciones fueron más comunes en pacientes que utilizaron ibuprofeno( 18,7 %), la forma clínica más frecuente fue el eritema multiforme menor (82,7 %), sobre todo fueron reacciones leves (94,8 %), que se presentaron con más frecuencia a los 10 ± 2,1 días de utilizar el fármaco. El 97,4 % de los pacientes se trató de modo ambulatorio. Conclusiones: Las RCAM no constituyen en un problema de salud en el Servicio de Dermatología del Hospital General Docente "Dr. Agostinho Neto", éstas presentan un espectro clínico coherente con lo que se refrenda en la literatura científica, pero se connota que el diagnóstico no suele ser con la precocidad que se demanda, pues los pacientes suelen solicitar evaluación médica luego de un periodo superior a siete días.


ABSTRACT Introduction: No studies in reference to adverse cutaneous reactions to drugs (CDRs) have been found at Guantanamo, need felt by the local dermatology faculty. Objective: Characterize the adverse cutaneous reactions to drugs in patients treated at the Dermatology Service of the General Teaching Hospital "Dr. Agostinho Neto" in Guantanamo, period 2018-2019. Method: A descriptive and transversal study was carried out with all patients (N=75) with the diagnosis of adverse cutaneous reactions to drugs referred to the Dermatology Clinic of the General Teaching Hospital "Dr. Agostinho Neto, the drug that caused the reaction, clinical diagnosis, type of reaction, time from ingestion of the drug until the symptoms appeared, number of reactions and medical behaviour were specified. Results: These reactions were more common in patients using ibuprofen (18.7%), the most frequent clinical form was erythema multiforme minor (82.7%), above all were mild reactions (94.8%), which occurred more often at 10 ± 2.1 days of using the drug. 97.4% of patients were treated on an outpatient basis. Conclusions: The (CDRs) does not constitute a health problem in the Dermatology Service of the General Teaching Hospital "Dr. Agostinho Neto", they present a clinical spectrum consistent with what is endorsed in the scientific literature, but it is noted that the diagnosis is not usually as early as demand, because patients usually request medical evaluation after a period exceeding seven days.


RESUMO Introdução: Em Guantánamo, não há estudos que abordem as reações cutâneas adversas a medicamentos (RCAM), uma necessidade sentida pelo claustro dos dermatologistas no território. Objetivo: Caracterizar as reações cutâneas adversas a medicamentos em pacientes atendidos no Serviço de Dermatologia do Hospital Geral de Ensino "Dr. Agostinho Neto" de Guantánamo no período 2018-2019. Método: Foi realizado um estudo descritivo e transversal com todos os pacientes (N=75) com diagnóstico de reações cutâneas adversas a medicamentos encaminhados ao serviço de Dermatologia do Hospital Geral de Ensino "Dr. Agostinho Neto", o medicamento que causou a reação, diagnóstico clínico, tipo de reação, tempo de evolução da ingestão do medicamento até o aparecimento de sintomas, número de reações e comportamento médico. Resultados: Essas reações foram mais comuns em pacientes que usaram ibuprofeno (18,7%), a forma clínica mais frequente foi eritema multiforme menor (82,7%), principalmente reações leves (94,8%), apresentou com maior frequência dentro de 10 ± 2,1 dias após o uso do medicamento. 97,4% dos pacientes foram tratados ambulatorialmente. Conclusões: As RCAMs não constituem um problema de saúde no Serviço de Dermatologia do Hospital Geral de Ensino "Dr. Agostinho Neto", estes apresentam um espectro clínico consistente com o que é endossado na literatura científica, mas há conotação de que o diagnóstico geralmente não é com a demanda precoce, uma vez que os pacientes geralmente solicitam avaliação médica após um período superior a sete dias


Subject(s)
Humans , Ibuprofen/adverse effects , Drug Eruptions/diagnosis , Epidemiology, Descriptive , Cross-Sectional Studies
8.
Einstein (Säo Paulo) ; 18: eRC5002, 2020. tab, graf
Article in English | LILACS | ID: biblio-1056030

ABSTRACT

ABSTRACT The fixed drug eruption is a non-immediate hypersensitivity reaction to drug, characterized by recurrent erythematous or violaceous, rounded, well-defined border plaques, which always appear in the same location every time the culprit drug is administered. The usual practice is to avoid the drug involved and to use a structurally different drug. However, there are situations in which there is no safe and effective therapy. In such situations, desensitization is the only option. We describe the case of a patient who presented fixed eruption due to sulfamethoxazole-trimethoprim, who underwent successful desensitization, but required a repeat procedure twice due to relapse after inadvertent full-dose reintroduction. In non-immediate hypersensitivity reaction to drug, the indication is controversial and there is no technical standardization. Furthermore, the time at which such tolerance is lost after discontinuing the drug involved is unknown. In severe non-immediate reactions of types II and III, desensitization is contraindicated. The patient underwent desensitisation to sulfamethoxazole-trimethoprim three times − the first with recurrence of lesions and the second and third without manifestations, all concluded successfully and with no premedication.


RESUMO A erupção fixa por drogas é uma reação de hipersensibilidade a medicamento não imediata, caracterizada por placas eritematosas ou violáceas, arredondadas, recorrentes, de bordas bem definidas e que aparecem sempre na mesma localização cada vez que o medicamento culpado é administrado. A prática habitual é evitar a droga envolvida e utilizar um medicamento estruturalmente diferente. Contudo, há situações em que não há terapêutica segura e eficaz. Em tais situações, a dessensibilização é a única opção. Descrevemos o caso de um paciente que apresentou erupção fixa por drogas por sulfametoxazol-trimetoprim, tendo sido submetido à dessensibilização com sucesso, mas necessitou repetição do procedimento duas vezes, por recidiva da reação após reintrodução inadvertida em dose plena. Em reação de hipersensibilidade a medicamento não imediata, a indicação é controversa e não há padronização técnica. Além disso, não se conhece o tempo durante o qual essa tolerância é perdida após a suspensão da droga envolvida. Nas reações não imediatas graves e dos tipos II e III, a dessensibilização está contraindicada. O paciente foi submetido a dessensibilização ao sulfametoxazol-trimetoprim por três vezes − a primeira com recorrência de lesões, e a segunda e terceira sem manifestações, sendo todas concluídas com sucesso e sem uso de pré-medicação.


Subject(s)
Humans , Male , Aged , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects , Desensitization, Immunologic/methods , Drug Eruptions/etiology , Drug Eruptions/drug therapy , Sulfamethoxazole/adverse effects , Trimethoprim/adverse effects , Drug Hypersensitivity/etiology , Drug Hypersensitivity/drug therapy
10.
An. bras. dermatol ; 94(6): 664-670, Nov.-Dec. 2019. tab, graf
Article in English | LILACS | ID: biblio-1054902

ABSTRACT

Abstract Background: Reports regarding the causative drugs of drug-induced cutaneous adverse reactions in China are indistinct, such that different regions have reported the spectrum of drugs differs substantially in different clinical conditions. Objective: To explore the causative drugs that led to cutaneous reactions. Methods: Adverse drug reaction reports from central China were collected and divided into cutaneous adverse reactions and severe cutaneous adverse reactions groups. Cases were reviewed retrospectively for causative drugs. Results: The male:female ratio was equal in both cutaneous adverse reactions and severe cutaneous adverse reactions. In cutaneous adverse reactions (n = 482), the highest incidence happened between 51 and 60 years of age and the top three causative drugs were antibiotics (48%), Chinese medicine (16%), and allopurinol (9%). In severe cutaneous adverse reactions (n = 126), the highest incidence happened between 41 and 50 years of age and the top three causative drugs were sedative-hypnotics and antiepileptics (39%), antibiotics (22%), and allopurinol (15%). Carbamazepine was the most frequently used single-drug (16/18) in sedative-hypnotics and antiepileptics. β-lactams were the most frequently used antibiotics that induced both cutaneous adverse reactions and severe cutaneous adverse reactions. Study limitations: The small sample size, retrospective design, collection of cutaneous adverse reactions and severe cutaneous adverse reactions at different time frames and locations, and exclusion of patients taking more than five medications are limitations of the study. Conclusions: Gender does not affect cutaneous adverse reactions and severe cutaneous adverse reactions. The top three drugs to induce cutaneous adverse reactions are antibiotics, Chinese medicine, and allopurinol, while those that triggered severe cutaneous adverse reactions are sedative-hypnotics and antiepileptics, antibiotics, and allopurinol. Carbamazepine is the most frequent single drug that induces severe cutaneous adverse reactions. β-lactams are the most frequently used antibiotics that induce both cutaneous adverse reactions and severe cutaneous adverse reactions.


Subject(s)
Humans , Infant , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Drug Eruptions/etiology , Drug Eruptions/epidemiology , China/epidemiology , Incidence , Retrospective Studies , Age Factors , Sex Distribution , Age Distribution , Hypnotics and Sedatives/adverse effects , Anti-Bacterial Agents/adverse effects , Anticonvulsants/adverse effects
11.
J. Health NPEPS ; 4(1): 319-329, jan.-jun. 2019.
Article in Portuguese | LILACS, BDENF | ID: biblio-999710

ABSTRACT

Objetivo: identificar as manifestações clínicas da necrólise epidérmica tóxica (NET) e síndrome de Stevens Johnson (SSJ). Método: trata-se de uma revisão narrativa. A busca dos artigos utilizou a ferramenta Publish or Perish, que ranqueia os trabalhos com base no número de citações recebidas. Foram realizadas duas buscas, pois apesar das doenças se relacionarem, possuem diagnósticos diferentes. Na primeira, os descritores utilizados foram: "necrólise epidérmica tóxica" e "manifestações clínicas", e na segunda os descritores foram: "Síndrome de Stevens-Johnson" e "manifestações clínicas". Resultados: após a leitura dos 12 artigos selecionados, entendeu-se que a patogênese da necrólise epidérmica tóxica e Síndrome de Stevens Johnson se dá pela hipersensibilidade tardia a fármacos. As manifestações clínicas se dão pelo aparecimento do eritema cutâneo com formação de máculas, pápulas, vesículas e bolhas associadas ou isoladas, como placas de urticária ou eritema extenso. Na NET é possível notar desprendimento extenso da epiderme maior que 30% da superfície corpórea, conhecido como sinal de Nikolsky, com acometimento de mucosas. Conclusão: A NET e SSJ são farmacodermias graves, com baixas incidências, mas elevada mortalidade. O reconhecimento precoce das doenças e a retirada do fármaco causador são essenciais para conduzir o tratamento, diminuindo por sua vez a taxa de mortalidade.(AU)


Objective: to identify the clinical manifestations of toxic epidermal necrolysis (TEN) and Stevens Johnson syndrome (SJS). Method: the articles search was done using the Publish or Perish computational tool, which ranks the articles based on the number of citations. Two separate searches were performed, because although the diseases are related, they have different diagnoses. In the first, the descriptors used were "Toxic Epidermal Necrolysis" and "clinical manifestations", and in the second the descriptors were "Stevens-Johnson Syndrome" and "clinical manifestations". Results: in total, 12 articles constituted the present revision. It was understood that the pathogenesis of TEN and SJS is due to late drugs hypersensitivity. The clinical manifestations are due to the appearance of cutaneous erythema with the formation of macules, papules, vesicles and associated or isolated blisters, such as urticaria plaques or extensive erythema. In the TEN it is possible to notice extensive detachment of the epidermis greater than 30% of the body surface, known as Nikolsky's signal, with mucous involvement. Conclusion: TEN and SJS are serious skin diseases, with low incidences but high mortality. Early recognition of disease and withdrawal of the causative drug are essential for conducting treatment, thus decreasing the mortality rate. Descriptors: Nursing; Dermatology; Signs and Symptoms; Treatment; Health Management.(AU)


Objectivo: identificar las manifestaciones clínicas de la necrólisis epidérmica tóxica (NET) y el síndrome de Stevens Johnson (SSJ). Método: la selección de los artículos consideró el número de citas recibidas por otras publicaciones. Se realizaron dos búsquedas, pues a pesar de las enfermedades se relacionan, poseen diferentes diagnósticos. En la primera, los descriptores utilizados fueron: "Toxic Epidermal Necrolysis" y "clinical manifestations", y en los segundos los descriptores fueron: "Stevens-Johnson Syndrome" y "clinical manifestations". Resultados: en total, 12 artículos constituyeron la presente revisión. Se ha comprobado que la patogénesis de TEN y SJS se debe a las drogas de larga duración. Las manifestaciones clínicas se deben a la apariencia de cutánea erythema con la formación de macules, papules, vesicles y asociados, o blister, tales como urticaria plaquetas o extensión erythema. En el TEN es posible que tenga un detalle detallado de las epidermis mayor que el 30% de la superficie del cuerpo, conocidas la Nikolsky de la señal, con mucous. Conclusión: la NET y SSJ son farmacodermias graves, con bajas incidencias pero elevada mortalidad. El reconocimiento precoz de las enfermedades y la retirada del fármaco causante son esenciales para conducir el tratamiento, disminuyendo a su vez la tasa de mortalidad. Descriptores: Enfermería; Dermatología; Signos y Síntomas; Tratamiento; Gestión en Salud.(AU)


Subject(s)
Humans , Stevens-Johnson Syndrome/diagnosis , Health Management , Drug-Related Side Effects and Adverse Reactions , Stevens-Johnson Syndrome/mortality , Drug Eruptions
12.
Korean Journal of Dermatology ; : 15-19, 2019.
Article in Korean | WPRIM | ID: wpr-719529

ABSTRACT

Anagen effluvium is an abrupt loss of hair in its growing phase due to an event that impairs the mitotic or metabolic activity of the hair follicle. Anagen effluvium is commonly associated with the administration of chemotherapy, radiation, and drugs as well as exposure to toxic chemicals. However, alopecia due to the administration of anti-tuberculosis drugs has rarely been reported in the literature. A 50-year-old female was diagnosed with intestinal tuberculosis and was started on anti-tuberculosis therapy with isoniazid, rifampicin, ethambutol, and pyrazinamide. After starting the treatment, erythematous to brown patches appeared all over her body, which was followed by diffuse hair loss on the scalp and body. Hair examination showed intact inner and outer root sheaths with fully pigmented hair bulbs, and histopathological examination of a scalp biopsy showed vacuolar degeneration in the interfollicular epidermis and perifollicular infiltration of mononuclear cells and eosinophils. The condition was diagnosed as anagen effluvium with drug eruption, and a potent corticosteroid lotion was prescribed for scalp application twice a day. After complete hair loss, the anti-tuberculosis medications were withdrawn, and hair regrowth started 4 months later. Here, we report a rare case of anagen effluvium with generalized drug eruption due to anti-tuberculosis medication.


Subject(s)
Female , Humans , Middle Aged , Alopecia , Biopsy , Drug Eruptions , Drug Therapy , Eosinophils , Epidermis , Ethambutol , Hair , Hair Follicle , Isoniazid , Pyrazinamide , Rifampin , Scalp , Tuberculosis
14.
Rev. chil. dermatol ; 35(3): 90-94, 2019. tab
Article in Spanish | LILACS | ID: biblio-1116406

ABSTRACT

INTRODUCCIÓN: La eritrodermia es un síndrome inflamatorio cutáneo infrecuente caracterizado por compromiso eritematoso generalizado y descamación, de más del 90% de superficie cutánea total. OBJETIVO: Caracterizar clínica e histopatológicamente a los pacientes con eritrodermia en un hospital universitario chileno. METODOLOGÍA: Estudio retrospectivo, realizado en el Hospital Clínico Universidad de Chile, basado en revisión de fichas clínicas e informes histopatológicos de pacientes con eritrodermia, entre 2005 y 2018. Se evaluó edad, sexo y variables clínicas (co-morbilidades, síntomas, días de evolución, ingreso hospitalario, informe histopatológico, diagnóstico y evolución). RESULTADOS: Total de 28 pacientes, 18 hombres (64%), edad promedio 59 años. Causa más frecuente de eritrodermia fue dermatosis pre-exis-tentes, con 15 casos (54%), que incluyen: psoriasis 9 (32%), dermatitis de contacto 3 (11%), PRP 2 (7%), dermatitis atópica 1 (4%). A estas le siguen: reacción adversa medicamentosa 6 (21%), idiopática 6 (21%) y Síndrome de Sezary 1 (4%). CONCLUSIÓN: El presente estudio corresponde a la primera serie de eritrodermias realizada en Chile. Destacan las dermatosis preexistentes como la principal causa, lo que se correlaciona con la literatura.


INTRODUCTION: Erythroderma is an infrequent cutaneous inflammatory disorder characterized by generalized erythematous compromise and desquamation, of more than 90% of total cutaneous surface. OBJECTIVE: Clinical and histopathological cha-racterization of patients with erythroderma in a Chilean university hospital. METHODOLOGY: Retrospective study, performed at the University of Chile Clinical Hospital, based on review of clinical records and histopatho-logical reports of patients with erythroderma, between 2005 and 2018. Age, sex and clinical variables were evaluated (co-morbidities, symp-toms, days of evolution, hospital admission, histopathological report, diagnosis and evolu-tion). RESULTS: A total of 28 patients, 18 were men (64%), average age 59 years. Most frequent cause of erythroderma was pre-existing dermatosis, with 13 cases (52%), which included: psoriasis 9 (32%), contact dermatitis 3 (11%), PRP 2 (7%), atopic dermatitis 1 (4%). These are followed by adverse drug eruption 6 (21%), idiopathic 6 (21%) and Sezary syndrome 1 (4%). CONCLUSION: The present study corresponds to the first series of erythrodermas performed in Chile. The pre-existing dermatoses were the main cause of erythroderma, which coincides with other reports.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Dermatitis, Exfoliative/etiology , Dermatitis, Exfoliative/pathology , Dermatitis, Exfoliative/epidemiology , Psoriasis/complications , Psoriasis/epidemiology , Clinical Evolution , Chile , Cross-Sectional Studies , Retrospective Studies , Drug Eruptions/complications , Drug Eruptions/epidemiology , Dermatitis, Atopic/complications , Dermatitis, Atopic/epidemiology , Dermatitis, Contact/complications , Dermatitis, Contact/epidemiology
15.
Acta Academiae Medicinae Sinicae ; (6): 278-282, 2019.
Article in Chinese | WPRIM | ID: wpr-776037

ABSTRACT

Multi-target anticancer drugs have a more comprehensive and extensive range of action,and there is an uncertain risk in the combination of two drugs.A case of acute toxicity induced by erlotinib combined with cabozantinib is reported in this article.


Subject(s)
Humans , Anilides , Drug Eruptions , Drug Therapy, Combination , Erlotinib Hydrochloride , Myocardial Infarction , Pyridines
16.
Korean Journal of Pediatrics ; : 75-78, 2019.
Article in English | WPRIM | ID: wpr-741363

ABSTRACT

Although rare, antihistamines can cause adverse effects, including drug-induced eruptions or anaphylaxis. A 4-year-old child visited the pediatric department of a hospital for skin eruptions after administration of antihistamines, (e.g., ucerax [hydroxyzine] or leptizine [levocetirizine]), for cholinergic rashes; he did not have pruritus. Skin prick, intradermal, and drug provocation tests were performed to determine the relationship between the antihistamines and eruptions. Levocetirizine induced wheals in the skin prick test and a rash in the oral drug provocation test. In contrast, ketotifen induced no reaction in the skin prick test but showed a positive reaction in the oral provocation test. Our case report highlights that children can experience the same types of adverse reactions as seen in adults, and cross-reactivity between various antihistamines can occur.


Subject(s)
Adult , Child , Child, Preschool , Humans , Anaphylaxis , Drug Eruptions , Exanthema , Histamine Antagonists , Ketotifen , Pruritus , Skin , Urticaria
17.
Korean Journal of Dermatology ; : 343-345, 2019.
Article in Korean | WPRIM | ID: wpr-759740

ABSTRACT

No abstract available.


Subject(s)
Humans , Drug Eruptions , Melanoma
18.
Korean Journal of Dermatology ; : 149-151, 2019.
Article in Korean | WPRIM | ID: wpr-759691

ABSTRACT

Lenalidomide is an immunomodulatory drug used for the treatment of multiple myeloma. Several cases of hematological, gastrointestinal, and cutaneous side effects have been reported for this drug. A 67-year-old patient with multiple myeloma had initially been treated with bortezomib, but the treatment was discontinued due to neurological side effects. The chemotherapeutic regimen of this patient was changed to lenalidomide. Ten days later, erythema and pruritus developed on the entire body. The lenalidomide dose was subsequently reduced and the patient was additionally treated with topical steroids. Because lenalidomide is supplied by the Korean Orphan Drug Center, physicians have limited experience with the drug, and hence, its side effects tend to be underestimated. In addition, the Korean literature lacks reports on such cases. We describe herein a case of lenalidomide-induced drug eruption presenting as a pruritic rash covering the whole body.


Subject(s)
Aged , Humans , Bortezomib , Drug Eruptions , Erythema , Exanthema , Multiple Myeloma , Orphan Drug Production , Pruritus , Steroids
19.
Allergy, Asthma & Immunology Research ; : 241-253, 2019.
Article in English | WPRIM | ID: wpr-739397

ABSTRACT

PURPOSE: Although severe cutaneous adverse drug reactions (SCARs) are rare, they are associated with high morbidity and mortality, and thus early diagnosis and treatment are critical for improving prognoses. However, few studies have reported the characteristics of SCARs in children. Thus, we aimed to evaluate the clinical characteristics, current management and prognosis of pediatric SCARs. METHODS: We analyzed pediatric data in the Korean SCARs registry, which was built retrospectively in 2016 with SCAR cases treated in 34 tertiary referral university hospitals during 2010–2015. Using these cases, we descriptively analyzed detailed data regarding etiology, clinical and laboratory features, treatment strategies, and prognosis. RESULTS: Forty-seven pediatric SCAR cases from 15 tertiary referral hospitals were included. The median patient age was 10 (interquartile range, 3-15.5) years and 68.1% (n = 32) were males. The culprit drug was identified in 95.7% (n = 45) of the patients; antibiotics (44.7%) and antiepileptic drugs (19.1%) were the most common and second most common culprits, respectively. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) cases presented with the largest area of skin involvement without permanent sequelae. Stevens-Johnson syndrome (SJS) cases involved relatively small areas of skin but serious sequelae in two children. Of 4 patients with toxic epidermal necrolysis (TEN), 1 died. Of all patients assessed, 36 (76.6%) received systemic steroids and 21 (44.7%) received intravenous immunoglobulin (IVIG). Thirteen (27.7%) received both systemic steroids and IVIG. Cyclosporine was administered to only 1 patient along with a systemic steroid. CONCLUSIONS: In patients with pediatric SCARs, including those with DRESS, SJS and TEN, clinical presentations were variable. Thus, there was no clear continuous disease spectrum. Although the mortality rate was low (2.1%), clinical suspicion may be the best tool for proactive SCAR management.


Subject(s)
Child , Humans , Male , Anti-Bacterial Agents , Anticonvulsants , Cicatrix , Cyclosporine , Drug Eruptions , Drug Hypersensitivity Syndrome , Drug-Related Side Effects and Adverse Reactions , Early Diagnosis , Hospitals, University , Immunoglobulins , Immunoglobulins, Intravenous , Korea , Mortality , Prognosis , Referral and Consultation , Retrospective Studies , Skin , Steroids , Stevens-Johnson Syndrome , Tertiary Care Centers
20.
Annals of Dermatology ; : 103-105, 2019.
Article in English | WPRIM | ID: wpr-739349

ABSTRACT

No abstract available.


Subject(s)
Humans , Drug Eruptions , Fibrosis , Lung
SELECTION OF CITATIONS
SEARCH DETAIL